GlassScriptPhysician profile
Geoffrey P Schwartz
NPI 1326046533
$2,345.60
in general payments reported to CMS, 2019-2025
27 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $118 · 2021: $169 · 2022: $261 · 2023: $240 · 2024: $470 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $398.47 | 2020-2025 | Rocklatan, Tryptyr, Clareon Panoptix Pro |
| Abbvie INC. | $380.56 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Lumigan |
| Allergan, INC. | $342.54 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $241.13 | 2019-2024 | Cequa |
| Rxsight INC | $134.41 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Amgen INC. | $107.90 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $99.25 | 2024-2025 | Vevye |
| Dompe US, INC. | $69.15 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.73 | 2019-2021 | |
| Biotissue Holdings INC. | $51.25 | 2019-2025 | |
| Oyster Point Pharma, INC. | $47.61 | 2023 | Tyrvaya |
| Thea Pharma INC. | $46.41 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $39.46 | 2023-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $39.05 | 2022-2025 | Xiidra |
| Sight Sciences, INC. | $35.92 | 2024 | Omni Surgical System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $33.94 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $31.44 | 2024 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $27.62 | 2024 | Cirrus Hd-Oct |
| Eyevance Pharmaceuticals LLC | $25.54 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $18.49 | 2019 | |
| Omeros Corporation | $18.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.99 | 2019 | |
| Rayner Intraocular Lenses Limited | $17.30 | 2022 | |
| Ocular Therapeutix, INC. | $14.71 | 2019 | |
| New World Medical,INC. | $13.57 | 2022 | |
| Eyepoint US, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geoffrey Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.